FY2029 EPS Estimates for CRBU Decreased by Analyst

Key Points

• Brookline Capital Management has reduced Caribou Biosciences' FY2029 earnings per share (EPS) estimate from $16.99 to $16.89.
• Caribou Biosciences reported an EPS of ($0.35) for the recent quarter, beating expectations of ($0.40), with revenue of $2.67 million exceeding forecasts.
• HC Wainwright has downgraded its price target on Caribou Biosciences’ shares from $9.00 to $3.00, indicating a significant reassessment of the company's stock value.

Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - Analysts at Brookline Capital Management dropped their FY2029 earnings per share estimates for shares of Caribou Biosciences in a research note issued to investors on Tuesday, August 12th. Brookline Capital Management analyst L. Cann now expects that the company will post earnings per share of $16.89 for the year, down from their prior forecast of $16.99. The consensus estimate for Caribou Biosciences' current full-year earnings is ($1.64) per share.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.05. The business had revenue of $2.67 million during the quarter, compared to analyst estimates of $1.64 million. Caribou Biosciences had a negative return on equity of 62.35% and a negative net margin of 1,800.93%.

A number of other brokerages also recently weighed in on CRBU. Wall Street Zen downgraded Caribou Biosciences from a "hold" rating to a "sell" rating in a research note on Saturday. HC Wainwright reissued a "buy" rating and issued a $3.00 price objective (down from $9.00) on shares of Caribou Biosciences in a research note on Monday, April 28th. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $6.67.

Caribou Biosciences Stock Performance

Shares of Caribou Biosciences stock traded down $0.1250 during trading on Thursday, hitting $1.7450. 503,046 shares of the stock traded hands, compared to its average volume of 1,345,888. The stock has a market cap of $162.49 million, a P/E ratio of -0.98 and a beta of 2.55. Caribou Biosciences has a twelve month low of $0.66 and a twelve month high of $2.9995. The company has a fifty day moving average price of $1.68 and a two-hundred day moving average price of $1.25.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in CRBU. JPMorgan Chase & Co. increased its position in Caribou Biosciences by 475.9% in the 4th quarter. JPMorgan Chase & Co. now owns 2,495,922 shares of the company's stock worth $3,969,000 after buying an additional 2,062,563 shares during the period. Wells Fargo & Company MN increased its position in Caribou Biosciences by 112.8% in the 4th quarter. Wells Fargo & Company MN now owns 91,988 shares of the company's stock worth $146,000 after buying an additional 48,759 shares during the period. Envestnet Asset Management Inc. increased its position in Caribou Biosciences by 43.4% in the 4th quarter. Envestnet Asset Management Inc. now owns 46,301 shares of the company's stock worth $74,000 after buying an additional 14,021 shares during the period. Russell Investments Group Ltd. increased its position in shares of Caribou Biosciences by 859.0% during the fourth quarter. Russell Investments Group Ltd. now owns 23,909 shares of the company's stock valued at $38,000 after purchasing an additional 21,416 shares during the period. Finally, Barclays PLC increased its position in shares of Caribou Biosciences by 12.0% during the fourth quarter. Barclays PLC now owns 145,417 shares of the company's stock valued at $231,000 after purchasing an additional 15,578 shares during the period. 77.51% of the stock is owned by institutional investors.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.